TTD | Drug: D0Y5ED

Drug General Information
Drug ID	D0Y5ED
Former ID	DIB015617
Drug Name	AV-203
Synonyms	ErbB3-targeted antibodies (cancer), AVEO/Biogen Idec
Drug Type	Antibody
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 1	[523911]
Company	Aveo oncology
Target and Pathway
Target(s)	Receptor protein-tyrosine kinase erbB-3	Target Info		[533093]
KEGG Pathway	ErbB signaling pathway
	Calcium signaling pathway
	Endocytosis
	Proteoglycans in cancer
	MicroRNAs in cancer
NetPath Pathway	TNFalpha Signaling Pathway
PANTHER Pathway	Cadherin signaling pathway
PANTHER Pathway	EGF receptor signaling pathway
Pathway Interaction Database	ErbB2/ErbB3 signaling events
	ErbB receptor signaling network
	a6b1 and a6b4 Integrin signaling
WikiPathways	ErbB Signaling Pathway
	Apoptosis-related network due to altered Notch3 in ovarian cancer
	Signaling Pathways in Glioblastoma
	miR-targeted genes in muscle cell - TarBase
	Heart Development
References
Ref 523911	ClinicalTrials.gov (NCT01603979) A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 533093	Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models. Clin Cancer Res. 2015 Mar 1;21(5):1106-14.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information